Since his second term started, former President Donald Trump embarked on a series of highly publicized initiatives, including announcements, negotiations, and floated proposals, all ostensibly aimed at reining in the pharmaceutical industry’s perceived excesses. These efforts emerged against a backdrop of widespread public discontent regarding the escalating costs of prescription medications in the United States, a concern that has consistently ranked high among American households for decades.
The public’s anxiety is palpable and well-documented. A recent nationwide poll conducted by the Kaiser Family Foundation (KFF) revealed that approximately 60% of American adults express significant worry about their ability, or their family’s ability, to afford prescription drug costs. This concern transcends political affiliations and socioeconomic strata, underscoring a fundamental challenge within the U.S. healthcare system. Furthermore, an overwhelming majority, over 80%, consider the price of prescription drugs in the U.S. to be "unreasonable." Consequently, a significant portion of the populace actively supports increased governmental regulation and intervention to mitigate these costs. This sentiment is reinforced by stark international comparisons: Americans typically pay about three times as much as individuals in other developed nations for identical prescription drugs, a disparity that highlights structural differences in drug pricing and negotiation.
A Chronology of Executive Actions
The Trump administration’s engagement with the pharmaceutical industry unfolded through several distinct phases. In July, the former President initiated a direct approach, sending letters to 17 prominent drug manufacturers. These letters were not mere inquiries but direct demands, urging these companies to voluntarily reduce their drug prices. This move was framed as a direct appeal to corporate responsibility and a precursor to potential governmental action if voluntary compliance was not met.
Following this initial outreach, President Trump reportedly engaged in individual negotiations with more than a dozen pharmaceutical executives at the White House. These meetings, often highlighted by the administration, were presented as high-level discussions designed to secure price concessions directly from industry leaders. The culmination of these efforts, as announced in December, was a claim that he had compelled these executives to agree to "most favored nation" (MFN) pricing specifically for Medicaid, the joint federal and state program providing healthcare coverage for low-income Americans. The MFN concept, in this context, suggested that the U.S. government would pay no more for certain drugs than the lowest price paid by any other developed country.
Further broadening his administration’s public-facing efforts, the "TrumpRx" initiative was unveiled. This platform was promoted as a resource where cash-paying patients could find discounted medicines. Concurrently, the administration pledged to expedite the approval process for biosimilar products – which are essentially generic versions of certain high-priced specialty drugs – by streamlining what it termed "FDA red tape." The intention was to foster greater competition and thereby drive down prices for complex biological medications.
Scrutinizing the Impact: Limited Scope and Opaque Details
Despite the grand pronouncements and significant media attention, the actual scope and tangible benefits of these initiatives have remained largely uncertain and, in many expert analyses, appear considerably less impactful than initially promised. A primary reason for this discrepancy lies in the inherent haziness surrounding many of the negotiation details, including precisely which drugs were covered by the alleged agreements and the specific terms of these deals.
Queries directed to the White House regarding the operational details and efficacy of TrumpRx often went unanswered, as exemplified by White House spokesperson Kush Desai’s silence on the matter. This lack of transparency has fueled skepticism among healthcare policy experts and patient advocates.
A critical point of analysis concerns the "most favored nation" pricing claim for Medicaid. It is crucial to note that Medicaid, by its very structure and federal mandates, already secures substantial discounts on prescription drugs. Federal law requires drug manufacturers to offer Medicaid their "best price," which is typically equivalent to the lowest price offered to any other purchaser. Therefore, the impact of a new "most favored nation" agreement on Medicaid, if truly distinct, would need to be rigorously demonstrated, and its actual incremental benefit has been questioned by many.
Moreover, for patients not covered by Medicaid, the benefits of TrumpRx have been limited. Many patients already have access to better options through existing commercial drug discount programs, which often offer a far wider array of products, or through their private insurance plans and associated drug company copayment cards. Consequently, for all the administration’s showmanship, the proportion of Americans likely to derive significant, material benefit from these specific executive actions remains slim, even if isolated individuals do manage to secure some savings.
Mark Cuban, the billionaire investor who has launched his own initiative to lower drug prices (Mark Cuban Cost Plus Drug Co.), offered a nuanced perspective. While acknowledging the limited scope, Cuban stated, "If it makes a difference to any patient, it’s a win." He specifically pointed to discounted pricing on TrumpRx for branded fertility drugs and GLP-1 weight loss drugs, particularly for individuals without insurance or whose plans lack coverage for these specific medications. Cuban’s own venture, Cost Plus Drugs, launched in 2022, aims to sell drugs cheaply by bypassing traditional middlemen, buying directly from manufacturers and selling to consumers, primarily focusing on generic medications. This model directly challenges the entrenched supply chain that often inflates drug costs.
Conversely, Aaron Kesselheim, a professor of medicine at Harvard Medical School whose research extensively focuses on drug prices, offered a more critical assessment. He characterized the Trump administration’s announcements as "one-off agreements made for publicity purposes. They don’t change anything about the way drugs are priced." Kesselheim further underscored the perceived weaknesses of these agreements, asserting, "The agreements are opaque and unenforceable." This opacity was evident, for instance, in the lack of clarity regarding which specific drugs would be subject to "most favored nation" prices or precisely how that designation was defined, making it clear that not all drugs would be affected.
The Reality of Drug Pricing: Business as Usual
Despite the high-profile efforts to influence drug prices, broader market trends indicated a continuation of established industry practices. Data from 46brooklyn, a consulting firm and data project specializing in tracking brand-name drug prices, revealed that close to 1,000 brand drugs experienced price increases in January. Furthermore, 2025 recorded the highest number of list price increases ever, a trend that predated and continued through the period of the Trump administration’s initiatives. Antonio Ciaccia, co-founder of 46brooklyn, succinctly summarized the situation: "This is not a material change, it’s business as usual."
Illustrating this trend, in the first week of the year, Pfizer, one of the major pharmaceutical companies that had engaged with the Trump administration, raised the list prices of 71 of its drugs by an average of 5%. During the same period, it lowered the price of only one drug, by a modest 9.8%, according to the data project. This pattern suggests that while individual deals might have been struck, they did not fundamentally alter the industry’s overarching pricing strategies or its regular practice of increasing list prices.
The True Game Changer: Medicare Drug Price Negotiation
Ironically, arguably the most significant victory for patients in the realm of drug pricing during this period came not from the Trump administration’s direct executive actions, but from its quiet continuation of a program initiated by the Biden administration: Medicare drug price negotiation for expensive medications. This landmark reform, enabled by the Inflation Reduction Act (IRA) of 2022, fundamentally altered the landscape of drug pricing in the United States by empowering Medicare, the largest single purchaser of prescription drugs, to negotiate prices directly with manufacturers.
The negotiated discounts on the initial list of 10 drugs – a critical selection including widely used medications such as blood thinners, insulins, and treatments for inflammatory disorders – officially went into effect on January 1. These negotiations yielded substantial price reductions, with some products seeing cuts of well over 50%. The estimated $6 billion in annual savings generated by this program played a crucial role in allowing Medicare to cap out-of-pocket spending on Part D prescription drugs for beneficiaries at $2,000 for 2025 and subsequent years, providing a significant financial safeguard for millions of seniors and individuals with disabilities.
The impact of the IRA extends beyond the initial tranche of drugs. An additional 15 high-priced medications, encompassing popular weight loss drugs and critical cancer treatments, were subject to negotiation. Discounted Medicare prices for these drugs are slated to take effect in the coming year. Furthermore, another 15 high-priced drugs are set for negotiation this year, demonstrating a sustained commitment to expanding the program’s reach. Cumulatively, the negotiated prices for these 40 drugs are projected to save Medicare well over $20 billion annually, a substantial sum that underscores the power of direct negotiation.
Despite the demonstrated success and public support for these negotiations, the pharmaceutical industry and its powerful lobbying arms have actively worked to limit the program’s impact. One notable example is the "One Big Beautiful Bill Act," which includes provisions that exempt drugs for rare diseases from price negotiations. This carve-out, while intended to protect incentives for developing orphan drugs, also represents a win for industry groups seeking to maintain high prices for certain lucrative medications.
Nonetheless, Kesselheim highlighted the historic significance of these legislative changes: "This is historic because it’s the first time the United States has negotiated prices, like every other developed country." He also addressed a common industry argument against negotiation, noting, "And guess what? Innovation didn’t stop." This statement directly challenges the pharmaceutical industry’s long-standing assertion that price controls stifle research and development, suggesting that a balance between affordability and innovation is achievable.
Crucially, it must be remembered that these substantial discounts benefit only Medicare enrollees. While the newer Trump administration initiatives might offer some relief to other patient populations, their impact is limited, often requiring patients to navigate complex systems to access potential savings. This highlights a persistent fragmentation in the U.S. drug pricing landscape, where different patient groups experience vastly different pricing structures.
Trump’s One-on-Ones: Deals on the Margins
The televised appearances of President Trump with the chief executives of major drug companies, while garnering media attention, largely resulted in deals whose impact on the average patient was minimal. For example, following a meeting between Trump and Albert Bourla, CEO of Pfizer, the company announced discounts on over 30 drugs. Bourla hailed the agreement as "a win for American patients, a win for American leadership, and a win for Pfizer."
These discounts were primarily channeled through TrumpRx, which, in turn, offered coupons co-branded with GoodRx.com. GoodRx already provides discount coupons for hundreds of medicines, suggesting that TrumpRx often served as an additional portal to existing discount mechanisms rather than introducing entirely new pricing structures.
Pfizer leveraged the deal for public relations, announcing it as part of a broader, "landmark" most favored nation (MFN) agreement with the U.S. government. The company claimed this would enable patients to pay lower prices for their prescription medicines while "strengthening America’s role as the global leader in biopharmaceutical innovation." Pfizer spokesperson Steven Danehy cited a press release from September, stating that the TrumpRx site offered patients savings "as high as 85%."
However, a closer examination of the TrumpRx list reveals important nuances. Many featured products are brand-name drugs that compete directly with far cheaper generic versions from other manufacturers. For instance, the cholesterol-lowering drug Colestid was listed on TrumpRx for "50% off" at $127.91. In stark contrast, generic versions of the same medication could be purchased for approximately $17 on Mark Cuban’s Cost Plus site. This discrepancy suggests that branded companies were not necessarily making significant sacrifices by offering these drugs at lower costs on Trump’s portal. Sean Tu, a patent law expert at the University of Alabama, argued that such sales were incremental: "That’s a sale they would not have made if not for TrumpRx." This indicates that the discounts might have primarily captured a market segment that would otherwise opt for generics or forgo the drug entirely.
Other drugs featured on TrumpRx were very old, such as Cortef (hydrocortisone). A 5-milligram branded Pfizer version was listed at $45 on TrumpRx, half its list price of $91.80. However, this same drug sells for significantly less on Cost Plus Drugs, further highlighting the relative nature of the "discounts." Still others, such as the $607.20 HIV treatment Viracept, are useful only in combination with other drugs that were not similarly discounted, limiting the overall financial benefit to patients.
A more recent addition to TrumpRx was Amgen’s Humira, which for years held the title of the world’s best-selling drug. Its price was reduced to $950 a dose from a list price of nearly $7,000. However, Humira lost its patent protection in 2023, paving the way for biosimilars – essentially generic equivalents – to enter the market. Tellingly, two of these biosimilars were also listed on TrumpRx for as little as $207.60 a dose, demonstrating that market competition from generics/biosimilars often provides far more substantial savings than executive-led "deals" on branded products nearing patent expiration.
Furthermore, most TrumpRx products are available only to customers without insurance who pay cash. This severely limits the program’s reach, especially for high-cost medications. For example, while the arthritis drug Xeljanz saw a drop from $2,277 to $1,518 a month on TrumpRx, this price point would still render it unaffordable for most uninsured cash-paying patients.
A Few Notable Deals and Their Context
While many of the TrumpRx offerings provided marginal savings, a few specific deals did generate headlines and offered more substantial, albeit still limited, benefits. The site, launched February 6, largely featured Pfizer’s 30 drugs (out of approximately 85 total offerings) alongside a scattering of other discounts.
Among the more impactful offerings were three fertility drugs from EMD Serono, a subsidiary of the pharmaceutical giant Merck KGaA. The most expensive of these, Gonal-F, with a list price of $966, was available for just $168 per IVF cycle using a TrumpRx coupon. These discounts have the potential to save women thousands of dollars, though fertility treatment as a whole remains prohibitively expensive for many, as drugs represent only a portion of the total cost. Sean Tipton, spokesperson for the American Society for Reproductive Medicine, estimated that TrumpRx discounts could reduce the $15,000-to-$25,000 cost of a single fertility treatment cycle by about 10% – a meaningful saving, but still a fraction of the total expense, especially given that women often require two or three cycles to achieve pregnancy. For comparison, in some European countries, each cycle costs approximately $3,000, underscoring the vast price disparities.
In exchange for lowering these prices, EMD Serono reportedly received concessions from the U.S. government, including the lifting of tariffs on its mostly overseas-produced medications. The company also secured the right to a sped-up FDA approval process for a fertility drug it had been extensively marketing in Europe, highlighting a quid pro quo approach that benefited the pharmaceutical company alongside the patient discounts.
Another newsworthy offering resulted from a deal with Novo Nordisk for Wegovy, its GLP-1 drug used for weight loss and diabetes. The price was reduced to as little as $199 a month for the pen. This came amid growing pressure on Novo Nordisk and Lilly & Co. (whose competitor Zepbound was also listed at $299) to lower the U.S. price of their GLP-1 drugs. Many insurers typically cover such drugs only for diabetes, leaving individuals seeking them for weight loss to pay out-of-pocket. The international context is also relevant here: the compounds have lost patent protection in India, and pressure from customers purchasing overseas is expected to intensify when generic Wegovy potentially goes on sale in Canada for as low as $73 a month.
The Enduring Challenge: Patent Thickets and Market Manipulation
Despite the Trump administration’s stated vow to approve biosimilars more rapidly to foster competition and lower prices, this approach may have limited impact on the core issue of high drug costs. The significant hurdle in bringing generics and biosimilars to market is often not merely the FDA approval process, but rather the arduous and time-consuming task of navigating the "thickets of patents" that U.S. law allows manufacturers to deploy to protect their intellectual property.
Professor Robin Feldman, a patent expert at the University of California Law-San Francisco, highlighted that dozens of patents are expected to keep Wegovy generics off the U.S. market until 2039. This extended protection contrasts sharply with other countries where generics become available much sooner. A recent report from the research group I-Mak further delved into various methods of patent manipulation that effectively delay generic entry into the U.S. market, long after these alternatives are available in European countries and Canada.
A salient example is the case of Otezla, a popular drug for psoriatic arthritis. In 2021, the FDA approved a generic version, yet it is not expected to hit the market until 2028 due to patent litigation and settlements. Such delays underscore how existing patent law and industry strategies can effectively circumvent efforts to introduce competition. Proposed reforms, such as requiring drugmakers to pay rebates to Medicare if they charge the program more than other developed countries for "single source" drugs and biologics, aim to address this by allowing Medicare to piggyback on the negotiated prices of other nations. However, these programs are still navigating the rulemaking process and, even if implemented, would primarily benefit Medicare beneficiaries, and only indirectly.
Ultimately, the landscape of U.S. drug pricing remains a complex and often bewildering challenge for the average patient-consumer. While some cash-paying individuals might uncover occasional bargains through initiatives like TrumpRx or commercial discount programs, securing the best deal often necessitates extensive "mixing and matching." This effectively forces patients to become highly discerning shoppers, scrutinizing prices for essential medicines with the same meticulousness they might apply to purchasing household staples like milk or eggs. The systemic issues that drive high drug costs – from patent protections and pharmaceutical lobbying to the opaque role of pharmacy benefit managers (PBMs) – largely remain unaddressed by executive gestures, emphasizing the critical role of comprehensive legislative reform in achieving sustainable affordability for all Americans.
Data reporter Maia Rosenfeld contributed to this article.
